These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 30646464)

  • 41. A case of isoniazid-induced liver injury diagnosed by use of the DLST, and successful reintroduction of isoniazid for pleural tuberculosis.
    Ikegame S; Wakamatsu K; Fujita M; Nakanishi Y; Kajiki A
    J Infect Chemother; 2011 Aug; 17(4):530-3. PubMed ID: 21188445
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Adverse events associated with treatment of latent tuberculosis in the general population.
    Smith BM; Schwartzman K; Bartlett G; Menzies D
    CMAJ; 2011 Feb; 183(3):E173-9. PubMed ID: 21220436
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Chemoprophylaxis with isoniazid in liver transplant recipients.
    Fábrega E; Sampedro B; Cabezas J; Casafont F; Mieses MÁ; Moraleja I; Crespo J; Pons-Romero F
    Liver Transpl; 2012 Sep; 18(9):1110-7. PubMed ID: 22645064
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Short-course isoniazid plus rifapentine directly observed therapy for latent tuberculosis in solid-organ transplant candidates.
    de Castilla DL; Rakita RM; Spitters CE; Narita M; Jain R; Limaye AP
    Transplantation; 2014 Jan; 97(2):206-11. PubMed ID: 24142036
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Treatment of latent tuberculosis infection induces changes in multifunctional Mycobacterium tuberculosis-specific CD4+ T cells.
    Sauzullo I; Mengoni F; Mascia C; Rossi R; Lichtner M; Vullo V; Mastroianni CM
    Med Microbiol Immunol; 2016 Feb; 205(1):37-45. PubMed ID: 26108901
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Treatment of latent tuberculosis infection: a network meta-analysis.
    Stagg HR; Zenner D; Harris RJ; Muñoz L; Lipman MC; Abubakar I
    Ann Intern Med; 2014 Sep; 161(6):419-28. PubMed ID: 25111745
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Isoniazid toxicity and TB development during biological therapy of patients with psoriasis in Colombia.
    Cataño J; Morales M
    J Dermatolog Treat; 2016 Oct; 27(5):414-7. PubMed ID: 27003177
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Survey of anti-tuberculosis drug-induced severe liver injury in Japan].
    Shigeto E;
    Kekkaku; 2007 May; 82(5):467-73. PubMed ID: 17564126
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Isoniazid-induced Pure Red Cell Aplasia in a Patient with Sarcoidosis: A Patient Summary and Review of the Literature.
    Saito Y; Sawada Y; Koga Y; Sunaga N; Tsukagoshi Y; Hachisu Y; Osaki T; Sakurai R; Kaira K; Ono A; Sato K; Koiso H; Oyama T; Hisada T; Yamada M
    Intern Med; 2017 Oct; 56(20):2753-2757. PubMed ID: 28924112
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Isoniazid hepatotoxicity in renal transplant recipients.
    Antony SJ; Ynares C; Dummer JS
    Clin Transplant; 1997 Feb; 11(1):34-7. PubMed ID: 9067692
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Isoniazid intervention for latent tuberculosis among 86 patients with rheumatologic disease administered with anti-TNFalpha.
    Hanta I; Ozbek S; Kuleci S; Sert M; Kocabas A
    Clin Rheumatol; 2007 Nov; 26(11):1867-70. PubMed ID: 17332973
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Cost-effectiveness of rifampin for 4 months and isoniazid for 6 months in the treatment of tuberculosis infection.
    Pina JM; Clotet L; Ferrer A; Sala MR; Garrido P; Salleras L; Domínguez A
    Respir Med; 2013 May; 107(5):768-77. PubMed ID: 23490222
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Two-month regimen of isoniazid, rifampin and pirazinamid for latent tuberculosis infection.
    Duarte R; Carvalho A; Correia A
    Public Health; 2012 Sep; 126(9):760-2. PubMed ID: 22633080
    [No Abstract]   [Full Text] [Related]  

  • 54. Acceptability and adherence to Isoniazid preventive therapy in HIV-infected patients clinically screened for latent tuberculosis in Dar es Salaam, Tanzania.
    Shayo GA; Moshiro C; Aboud S; Bakari M; Mugusi FM
    BMC Infect Dis; 2015 Aug; 15():368. PubMed ID: 26306511
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Isoniazid-associated hepatitis and antiretroviral drugs during tuberculosis prophylaxis in hiv-infected adults in Botswana.
    Tedla Z; Nyirenda S; Peeler C; Agizew T; Sibanda T; Motsamai O; Vernon A; Wells CD; Samandari T
    Am J Respir Crit Care Med; 2010 Jul; 182(2):278-85. PubMed ID: 20378730
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Three months of weekly rifapentine plus isoniazid for latent tuberculosis treatment in solid organ transplant candidates.
    Knoll BM; Nog R; Wu Y; Dhand A
    Infection; 2017 Jun; 45(3):335-339. PubMed ID: 28276008
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Assessment of age-related isoniazid hepatotoxicity during treatment of latent tuberculosis infection.
    Aziz H; Shubair M; Debari VA; Ismail M; Khan MA
    Curr Med Res Opin; 2006 Jan; 22(1):217-21. PubMed ID: 16393447
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Female sex and discontinuation of isoniazid due to adverse effects during the treatment of latent tuberculosis.
    Pettit AC; Bethel J; Hirsch-Moverman Y; Colson PW; Sterling TR;
    J Infect; 2013 Nov; 67(5):424-32. PubMed ID: 23845828
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Isoniazid-inducedtoxic hepatitis].
    Kristensen KL; Nordholm AC; Clausen MR; Katzenstein TL
    Ugeskr Laeger; 2021 Feb; 183(6):. PubMed ID: 33570026
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Current treatment options for latent tuberculosis infection.
    Bocchino M; Matarese A; Sanduzzi A
    J Rheumatol Suppl; 2014 May; 91():71-7. PubMed ID: 24789003
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.